HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on BioCardia (NASDAQ:BCDA) and maintained a $9 price target.

June 21, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on BioCardia and maintained a $9 price target.
The reiteration of the Buy rating and maintenance of the $9 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for BioCardia's stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100